BIO Mid-America Venture Forum 2007 Presenter Profiles

BIO Mid-America Venture Forum 2007 takes place Sept. 24 — 26, 2007 at the Hyatt Regency Milwaukee. Listed below are BIO Mid-America Venture Forum presenter profiles. For in-depth information about the event, visit http://bma.bio.org/opencms/bma/2007/index.jsp.

Business Wire is the official news wire for the BIO Mid-America Venture Forum. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire’s trade show, conference, and event news resource.

Company:

AxioMed Spine Corporation

Investor Relations Contact:

Patrick A. McBrayer

Investor Relations Contact Phone:

216-587-5566

Web:

www.axiomed.com

Date of Presentation:

Sept. 25, 2007, 11:30 a.m., Room B

AxioMed Spine Corporation located in Cleveland, Ohio was formed in 2001 to develop products for restoring native function to patients with degenerative spine disease; thereby advancing the standard of care beyond fusion and first generation artificial discs. Led by an experienced and proven management team, AxioMed has developed next generation technology for artificial disc implants that is characterized by: the replication of the native function of the natural human intervertebral disc; least-invasive surgical approach; strong intellectual property with patents on design, exclusive license to patented materials, and proprietary manufacturing processes; and collaboration with and endorsement of influential spine surgeons worldwide.

 

 

Company:

C5-6 Technologies

Investor Relations Contact:

John Biondi

Investor Relations Contact Phone:

608.836.3587 x321

Web:

www.c56technologies.com

Date of Presentation:

Wednesday, September 26

C5-6 Technologies is a bio-energy company possessing a technical platform capable of producing high temperature enzymes that are extremely efficient convertors of agricultural feedstocks to 5 and 6 Carbon sugars for biofuels production. The Company’s technology promises to improve the current corn ethanol production process by 10%; produce ethanol and concentrated soy protein from soy meal in what promises to be the most profitable ethanol process available; and convert a variety of cellulosic feedstocks within the dry mill process–the most cost effective method of converting these materials available. The Company is a recent recipient of DOE and USDA grant awards and is located in the Madison, Wisconsin area.

 

 

Company:

Celleration® Inc.

Investor Relations Contact:

Kevin Nickels

Investor Relations Contact Phone:

(952)224-8701

Web:

www.celleration.com

Date of Presentation:

25-Sep-07

Celleration®, Inc., a Minnesota-based medical device company, has produced an impressive growing body of clinical research with an exciting new wound healing device, the MIST Therapy® System. MIST Therapy, a painless non-contact ultrasound device that is easy to use with a short treatment time is a proven healing device that helps wounds heal faster. The device promotes wound healing through cellular stimulation while removing bacteria from the wound. MIST Therapy’s body of evidence includes seven peer reviewed publications that demonstrate the safety and efficacy of the device. Across the United States, MIST Therapy has demonstrated tremendous clinical and economic benefits.

 

 

Company:

CENTROSE

Investor Relations Contact:

Dr. James Prudent

Investor Relations Contact Phone:

Cell: 608.209.8933

Office:

608.836.0207

Web:

www.centrose.info

Date of Presentation:

26-Sep-07

Centrose is applying scientific breakthroughs in sugar chemistry in order to discover, develop and commercialize small molecule therapeutics. Centrose offers high throughput, rapid and low cost approaches for the attachment of any sugar molecule to any compound. Sugars are critical molecules that regulate biological processes and pathways in the human body and play fundamental roles in diseases as well as in drug action. Additionally, compounds that once did not contain sugar attachments have been found to have novel therapeutic properties after sugar addition. Centrose is actively commercializing lead compounds as well as the platform that discovers them

 

 

Company:

DiObex, Inc.

Investor Relations Contact:

CEO David Cory

Investor Relations Contact Phone:

(415) 551-0400

Web:

www.diobex.com

Date of Presentation:

September 26th, 2007

DiObex, Inc. is a biotechnology company developing novel products for the treatment of metabolic diseases. The company’s pipeline includes therapeutics for type 1 and type 2 diabetes, dyslipidemia, obesity, and diabetic nephropathy.

 

DIO-901, a very low dose glucagon, is in Phase 2 development for the prevention of insulin-induced hypoglycemia in patients with type 1 diabetes (T1DM). It has received Fast Track status from the Food and Drug Administration.

 

DIO-902 is a novel cortisol synthesis inhibitor in Phase 2 development for type 2 diabetes (T2DM). Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome.

 

 

Company:

EraGen BioSciences Inc.

Investor Relations Contact:

Rod Hise

Investor Relations Contact Phone:

608 807-4607

Web:

www.eragen.com

Date of Presentation:

25-Sep-07

EraGen BioSciences is a developer, manufacturer and marketer of next-generation molecular diagnostic products for the early, accurate diagnosis of critical diseases. The company’s goal is to become a leader in molecular diagnostics, serving the significant unmet needs of the rapidly growing $2.5 billion molecular diagnostics market. EraGen’s strategy is founded on three fundamental value drivers: its patented MultiCode® DNA and RNA platform chemistry; its menu and pipeline of easy-to-use, accurate products for a high-value, high-growth market, and; demonstrated excellence in business and product performance with market-leading customers and partners.

 

 

Company:

InvivoSciences LLC

Investor Relations Contact:

CEO, Co-Founder Ayla Annac

Investor Relations Contact Phone:

cell : 608 628 8035

Web:

www.invivosciences.com

Date of Presentation:

September 26th, morning

InvivoSciences LLC (IVS) bridges the gap in preclinical research performed using animal models and cell culture systems to reduce the costs of drug discovery. IVS develops and commercializes rapid in vitro biological profiling systems for drug screening, preclinical development, and toxicology assessments for research, clinical, cosmetic, and food market applications. The company provides a proprietary technology that combines miniaturized engineered tissues and an automated assay system to determine Physiologically Based Pharmacokinetic data and Biologically Based Dose-Response data. IVS’s human cell-derived tissue system assists our customers to minimize animal studies, yet still to predict clinical outcomes with sufficiently high accuracy to meet FDA requirements.

 

 

Company:

NanoMed Pharmaceuticals, Inc.

Investor Relations Contact:

Stephen Benoit

Investor Relations Contact Phone:

(269) 488-8525

Web:

www.nanomedpharm.com

Date of Presentation:

25-Sep-07

NanoMed Pharmaceuticals®, Inc. is an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases. The company’s lead product is a nanoparticle formulation of an FDA-approved cancer drug used to treat adults diagnosed with acute myeloid leukemia. This lead product, which is expected to enter human clinical trials in 2008, is being developed using Nanotemplate Engineering, the company’s proprietary nanoparticle manufacturing technology used to formulate small molecules, peptides, proteins, plasmid DNA, and diagnostic agents. NanoMed is headquartered in Kalamazoo, Michigan.

 

 

Company:

Quintessence Biosciences, Inc.

Investor Relations Contact:

Ralph Kauten

Investor Relations Contact Phone:

608-441-2951

Web:

www.quintbio.com

Date of Presentation:

25-Sep-07

Quintessence Biosciences is a private, preclinical stage biopharmaceutical company developing novel, proprietary, anti-cancer compounds based on its EVade™ ribonuclease technology platform. The company expects to initiate clinical studies with its lead compound (QBI-139) in the first half of 2008 targeting solid tumors, such as colon and lung cancer. In vitro and in vivo preclinical data to date has demonstrated an excellent efficacy profile in murine xenograft models relative to marketed anti cancer drugs. The company is currently raising $5 million to fund the development of QBI-139 and develop other compounds in the pipeline.

 

 

Company:

RhinoCyte™ Inc.

Investor Relations Contact:

George Emont

Investor Relations Contact Phone:

502-569-1590

Web:

www.rhinocyte.com

Date of Presentation:

25-Sep-07

RhinoCyteTM, Inc. is an early stage biotechnology company focused on commercializing autologous adult olfactory-derived stem cell therapies to treat spinal cord injury and neurodegenerative disorders such as Parkinson’s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

 

RhinoCyte’s proprietary technology involves harvesting, isolating, engineering, expanding, cyropreserving and engrafting autologous adult progenitors, circumventing histocompatibility, immunosuppression and ethical concerns. The feasibility of this technology to treat neurodegenerative diseases has been demonstrated through published in vitro and in vivo studies.

 

RhinoCyteTM seeks to raise Series B $10-12 Million to continue developing the technology and fund the Phase I clinical trial of the lead product.

 

 

Company:

SanoGene Therapeutics Inc.

Investor Relations Contact:

Caralynn V. Nowinski

Investor Relations Contact Phone:

(312) 927-3570

Web:

www.sanogene.com

Date of Presentation:

9/25/2007

SanoGene Therapeutics Inc. is an early stage biotechnology company, utilizing innovative RNAi-based technologies to develop biopharmaceutical products for deadly cancers. The Company’s platform technology combines the capabilities of multiple therapeutics into one deliverable product with synergistic effects. This proprietary multi-targeted approach is employed in the development of SanoGene’s lead candidate, SG-1311, for the treatment of glioblastoma multiforme, the most common and deadliest form of brain cancer. Founded at the University of Illinois at Chicago, SanoGene brings together scientific and managerial talent, proprietary technology and a scalable business model to deliver the next generation of cancer treatment.

 

 

Company:

Tissue Genetics, Inc

Investor Relations Contact:

Kimberly A. Gibson

Investor Relations Contact Phone:

720-364-1990

Web:

http//:www.tissuegenetics.com

Date of Presentation:

25-Sep-07

Tissue Genetics is a predictive medicine company tailoring treatment to need by pairing the proprietary tissue-based diagnostic tests with a complimentary therapy. Thereby specifically treating patients based on their diagnostic test results. In order to identify Hereditary Cancer, the largest hereditary disease group, we created a specific antibody that proved successful, first in identifying the hereditary cancers and second in identifying a specific area on the gene that indicates expected treatment. This specific site is also affected in some sporadic cancers and they can be treated as well. We are identifying which drugs are best suited as a treatment.

 

 

Company:

Venomix, Inc.

Investor Relations Contact:

John L. McIntyre, Pres., CEO

Investor Relations Contact Phone:

(616) 889-9611

Web:

www.Venomix.net

Date of Presentation:

25-Sep-07

VENOMIX, Inc. is developing a new generation of insecticides using peptides from spiders. The company’s technology is based on ground-breaking research conducted at the University of Connecticut. Over 50 unique, spider-venom peptides with novel sites of action have been identified. This patented technology is exclusively licensed to Venomix.

 

Products under development have a unique mode of action, are highly effective against insects and related pests and are harmless to non-target species, including humans. Target markets include agriculture, animal health and specialty non-crop uses such as household insects. VENOMIX products will be ideally suited for the environmentally conscious twenty-first century. www.Venomix.net

 

 

Company:

Ventaira Pharmaceuticals

Investor Relations Contact:

Susan Neath

Investor Relations Contact Phone:

619-849-6007

Web:

www.ventaira.com

Date of Presentation:

26-Sep

Ventaira is a specialty pharmaceutical company that uses its proprietary pulmonary drug delivery technology, Mystic™ (Electrohydrodynamic EHD), and formulation capabilities to deliver respiratory and systemically active drugs more efficiently and effectively. Ventaira is currently developing its own proprietary drugs for the treatment of a wide variety of conditions and also looks to create opportunities for existing drugs that may be more easily delivered via inhalation. Ventaira has an exclusive license on a portfolio of patents for its Mystic technology.

Note to Editors: Business Wire’s PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire’s online event calendar. For information, email tradeshow (at) businesswire.com.